USD 0.0
(0.0%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2021 | 50.96 Million USD | 13.62% |
2020 | 44.85 Million USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2022 Q2 | 13.54 Million USD | -19.85% |
2022 Q1 | 16.89 Million USD | 0.0% |
2021 FY | 50.96 Million USD | 13.62% |
2021 Q2 | 15.46 Million USD | 0.0% |
2020 FY | 44.85 Million USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
AstraZeneca PLC | 29.57 Billion USD | 99.828% |
Bristol-Myers Squibb Company PFD CONV 2 | 17.07 Billion USD | 99.701% |
CSPC Pharmaceutical Group Limited | 2.14 Billion USD | 97.626% |
Novartis AG | 24.87 Billion USD | 99.795% |
PT Kalbe Farma Tbk. | 11823.24 Billion USD | 100.0% |